An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects.

Trial Profile

An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2010

At a glance

  • Drugs Aspirin; Elinogrel
  • Indications Embolism and thrombosis; Renal impairment
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Nov 2010 Primary endpoints identified as reported by ClinicalTrials.gov.
    • 23 Nov 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top